Scarica l'app Stockscreener
72.40
2.19%
1.55
Dopo l'orario di chiusura:
74.40
2.00
+2.76%
Precedente Chiudi:
$70.85
Aprire:
$71.17
Volume 24 ore:
29,946
Relative Volume:
0.35
Capitalizzazione di mercato:
$77.49M
Reddito:
$7.10M
Utile/perdita netta:
$-39.43M
Rapporto P/E:
-77.02
EPS:
-0.94
Flusso di cassa netto:
$-46.50M
1 W Prestazione:
-6.64%
1M Prestazione:
-10.14%
6M Prestazione:
-86.68%
1 anno Prestazione:
-90.34%
Intervallo 1D:
$71.00
$74.40
Intervallo di 1 settimana:
$69.02
$83.49
Portata 52W:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
72.40 | 75.84M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target - TipRanks
Experimental enzyme therapy stabilizes skills for 6 years in fatal disorder - stocktitan.net
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - BioSpace
Spruce Biosciences Makes Two SVP Appointments - Contract Pharma
Spruce Biosciences (NASDAQ:SPRB) Shares Up 0.6%Time to Buy? - MarketBeat
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - BioSpace
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium - Investing News Network
Harbour BioMed Exercises Warrant to Acquire 3.8% of Spruce Biosciences Inc. - intellectia.ai
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Harbour BioMed Acquires Stake in U.S. Partner Spruce Biosciences, Signaling Strategic Shift in Chinese Biotech - IndexBox
Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership - intellectia.ai
Harbour BioMed Expands Stake in Spruce Biosciences (SPRB) - GuruFocus
Harbour BioMed Exercises Agreement to Buy Spruce Biosciences Common Stock - Contract Pharma
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences (SPRB) - Intellectia AI
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences - Intellectia AI
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deep - GuruFocus
Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences - Nasdaq
HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise - TipRanks
Harbour BioMed buys into Spruce to back new hormone disorder drug - Stock Titan
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - Barchart.com
Harbour BioMed takes stake in Spruce Biosciences - MSN
HBM Lifts Spruce Biosciences Stake to About 3.8% After Warrant Exercise - marketscreener.com
Spruce Biosciences (SPRB) Price Target Increased by 10.02% to 235.11 - Nasdaq
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - BioSpace
Spruce Biosciences secures up to $50 million in growth capital from Avenue Capital - marketscreener.com
Spruce Biosciences Signs Multiple Financing Agreements - TradingView — Track All Markets
Spruce Biosciences (SPRB) price target increased by 55.76% to 213.69 - MSN
MSN Money - MSN
Spruce Biosciences assumed with a buy at HC Wainwright - MSN
Spruce Biosciences (NASDAQ:SPRB) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Equities Analysts Offer Predictions for SPRB FY2025 Earnings - MarketBeat
Spruce Biosciences initiated with an Outperform at Oppenheimer - Yahoo Finance
Oppenheimer Initiates Coverage on SPRB with "Outperform" Rating - GuruFocus
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Yahoo Finance
Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength - TradingView — Track All Markets
Oppenheimer initiates coverage on Spruce Biosciences stock with Outperform rating - Investing.com Australia
Oppenheimer Initiates Coverage of Spruce Biosciences (SPRB) with Outperform Recommendation - Nasdaq
Revenue per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView — Track All Markets
Spruce Biosciences stock rating resumed at Buy by H.C. Wainwright - Investing.com Nigeria
HC Wainwright Reaffirms Buy Rating for Spruce Biosciences (NASDAQ:SPRB) - MarketBeat
SPRB Stock: HC Wainwright & Co. Initiates Coverage with Buy Rati - GuruFocus
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to S&P TMI Index - marketscreener.com
With Spruce Biosciences Stock Sliding, Have You Assessed The Risk? - Trefis
[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Spruce Biosciences CEO reports RSU vesting and option repricing | SPRB SEC FilingForm 4 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Spruce Biosciences Appoints Keli Walbert as Director - The Globe and Mail
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):